# Title

 Food and Drugs. PART 203â€”PRESCRIPTION DRUG MARKETING


# ID

 CFR-2018-title21-vol4.Pt. 203


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                            |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(125000.0, 'USD')]                                                                                                                                                                                                               |
| Constraints | ['more than', 'before', 'after', 'minimum', 'at least', 'within', 'later than']                                                                                                                                                   |
| Duration    | ['3.0 year', '30.0 day', '6.0 month', '2.0 day']                                                                                                                                                                                  |
| Condition   | ['subject to', 'until', 'where', 'provided that', 'when', 'if']                                                                                                                                                                   |
| Entities    | ['Investigation', 'Risperidone', 'United States', 'Dosage', 'Scope', 'G112', 'Sample', 'Fulfillment', 'Request', 'Research, Office', 'Application', 'Purpose', 'Food', 'Rm', 'Surveillance, Office', 'Drug', 'Research', 'Blood'] |


# Structured Analysis With Context

 


## Money

| Money             | Context                                                                                                                                                                                                                                                                                                                                                                                             |
|:------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (125000.0, 'USD') | A person who provides information leading to the institution of a criminal proceeding against, and conviction of, a person for the sale, purchase, or trade of a drug sample, or the offer to sell, purchase, or trade a drug sample, in violation of section 503(c)(1) of the act, is entitled to one-half the criminal fine imposed and collected for such violation, but not more than $125,000. |


## Constraints

| Constraints   | Context                                                                                                                               |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------------------|
| minimum       | against drug diversion by establishing procedures, requirements, and minimum standards for the distribution of prescription drugs and |
| before        | set forth in paragraph (b) of this section, before the delivery of the drug sample; (2) The                                           |
| before        | a written request signed by the licensed practitioner before the delivery of the drug sample; (2) The                                 |
| at least      | drug samples by means of representatives shall conduct, at least annually, a complete and accurate physical inventory of              |
| more than     | samples be delivered over a period of not more than 6 months, with the actual delivery dates for                                      |
| within        | requested forms, reports, records, or other required documents within 2 business days of a request by an                              |
| within        | (1) Notify FDA, by telephone or in writing, within 5 working days; (2) Immediately initiate an investigation;                         |
| later than    | for and the results of the investigation, not later than 30 days after the date of the initial                                        |
| after         | of the investigation, not later than 30 days after the date of the initial notification in paragraph                                  |
| within        | (1) Notify FDA, by telephone or in writing, within 5 working days of becoming aware of a                                              |
| later than    | for and the results of the investigation, not later than 30 days after the date of the initial                                        |
| after         | of the investigation, not later than 30 days after the date of the initial notification in paragraph                                  |
| within        | shall notify FDA, by telephone or in writing, within 30 days of becoming aware of the conviction                                      |
| later than    | provide FDA with a complete written report not later than 30 days after the date of the initial                                       |
| after         | complete written report not later than 30 days after  the date of the initial notification.                                           |
| within        | distributes drug samples shall inform FDA in writing within 30 days of selecting the individual responsible for                       |
| within        | sample is deemed to be a drug sample within  the meaning of the act.                                                                  |
| within        | sample is deemed to be a drug sample within  the meaning of the act.                                                                  |
| at least      | be retained by the recipient charitable institution for at least 3 years, containing the following information: (1) The               |
| at least      | (g) Each recipient charitable institution shall conduct,  at least annually, an inventory of prescription drug sample stocks          |
| within        | (i) A charitable institution shall notify FDA  within 5 working days of becoming aware of a                                           |
| before        | prior sale, purchase, or trade of such drug. before                                                                                   |
| at least      | distribution of drug samples, shall retain them for at least  3 years after the date of their creation.                               |
| after         | shall retain them for at least 3 years after  the date of their creation.                                                             |
| within        | The records shall be made available  within  2 business days of a request.                                                            |
| more than     | imposed and collected for such violation, but not more than  $125,000.                                                                |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6.0 month  | An arrangement by which a licensed practitioner requests in writing that a specified number of drug samples be delivered over a period of not more than 6 months, with the actual delivery dates for parts of the order to be set by subsequent oral communication or electronic transmission, is not considered to be a standing request.                                                                   |
| 2.0 day    | A manufacturer or authorized distributor of record that contracts with a third party to maintain some or all of its records shall produce requested forms, reports, records, or other required documents within 2 business days of a request by an authorized representative of FDA or another Federal, State, or local regulatory or law enforcement official.                                              |
| 30.0 day   | A manufacturer or authorized distributor of record that has reason to believe that any person has falsified drug sample requests, receipts, or records, or is diverting drug samples, shall:                                                                                                                                                                                                                 |
|            |                       (1) Notify FDA, by telephone or in writing, within 5 working days;                                                                                                                                                                                                                                                                                                                     |
|            |                       (2) Immediately initiate an investigation; and                                                                                                                                                                                                                                                                                                                                         |
|            |                       (3) Provide FDA with a complete written report, including the reason for and the results of the investigation, not later than 30 days after the date of the initial notification in paragraph (a)(1) of this section.                                                                                                                                                                  |
| 30.0 day   | (3) Provide FDA with a complete written report, including the reason for and the results of the investigation, not later than 30 days after the date of the initial notification in paragraph (b)(1) of this section.                                                                                                                                                                                        |
| 30.0 day   | (1) A manufacturer or authorized distributor of record that distributes drug samples shall notify FDA, by telephone or in writing, within 30 days of becoming aware of the conviction of one or more of its representatives for a violation of section 503(c)(1) of the act or any State law involving the sale, purchase, or trade of a drug sample or the offer to sell, purchase, or trade a drug sample. |
| 30.0 day   | (2) A manufacturer or authorized distributor of record shall provide FDA with a complete written report not later than 30 days after the date of the initial notification.                                                                                                                                                                                                                                   |
| 30.0 day   | A manufacturer or authorized distributor of record that distributes drug samples shall inform FDA in writing within 30 days of selecting the individual responsible for responding to a request for information about drug samples of that individual's name, business address, and telephone number.                                                                                                        |
| 3.0 year   | (e) The recipient charitable institution shall prepare at the time of collection or delivery of a drug sample a complete and accurate donation record, a copy of which shall be retained by the recipient charitable institution for at least 3 years, containing the following information:                                                                                                                 |
|            |                       (1) The name, address, and telephone number of the licensed practitioner (or donating charitable institution);                                                                                                                                                                                                                                                                         |
|            |                       (2) The manufacturer, brand name, quantity, and lot or control number of the drug sample donated; and                                                                                                                                                                                                                                                                                  |
|            |                       (3) The date of the donation.                                                                                                                                                                                                                                                                                                                                                          |
| 3.0 year   | (b) The drug origin statement is subject to the record retention requirements of &#167;&#8201;203.60 and must be retained by all wholesale distributors involved in the distribution of the drug product, whether authorized or unauthorized, for 3 years.                                                                                                                                                   |
| 3.0 year   | Any person required to create or maintain reports, lists, or other records under PDMA, PDA, or this part, including records relating to the distribution of drug samples, shall retain them for at least 3 years after the date of their creation.                                                                                                                                                           |
| 2.0 day    | The records shall be made available within 2 business days of a request.                                                                                                                                                                                                                                                                                                                                     |


## Condition

| Condition     | Context                                                                                                                                         |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------------------|
| when          | represented for use in a drug and that, when used in the manufacturing, processing, or packaging of                                             |
| when          | in emergencies or during hours of the day when necessary drugs cannot be obtained; and transfers of                                             |
| when          | (u) Ongoing relationship means an association that exists  when a manufacturer and a distributor enter into a                                   |
| subject to    | including finished dosage forms and bulk drug substances subject to  section 503(b) of the act.                                                 |
| when          | blood components intended for transfusion; (9) Drug returns, when conducted by a hospital, health care entity, or                               |
| if            | to reimport a prescription drug or insulin-containing drug if it determines that such reimportation is required for                             |
| where         | of the FDA District Office in the district where reimportation is sought (addresses found in part 5,                                            |
| provided that | stem/progenitor cells or performing diagnostic testing of specimens provided that these specimens are tested together with specimens undergoing |
| when          | set forth in paragraph (c) of this section, when the drug sample is delivered; and (4) The                                                      |
| where         | The practitioner's State license or authorization number or, where a scheduled drug product is requested, the practitioner's                    |
| if            | the manufacturer and the authorized distributor of record, if the drug sample is requested from an authorized                                   |
| if            | sample delivered; and the date of the delivery. if                                                                                              |
| if            | sample delivered; and the date of the delivery. if                                                                                              |
| when          | set forth in paragraph (c) of this section, when the drug sample is delivered; (4) The receipt                                                  |
| where         | The practitioner's State license or authorization number, or, where a scheduled drug product is requested, the practitioner's                   |
| if            | the manufacturer and the authorized distributor of record, if the drug sample is requested from an authorized                                   |
| if            | sample delivered; and the date of the delivery. if                                                                                              |
| if            | sample delivered; and the date of the delivery. if                                                                                              |
| where         | who distribute drug samples and of the sites where  drug samples are stored.                                                                    |
| provided that | electronic data transfer) or by any other system, provided that the method for transmission meets the security requirements                     |
| when          | of nonresponse, and the manufacturer's or distributor's response when such patterns are found; (2) Conducting the annual                        |
| if            | outside container or packaging of the sample unit, if  any, an ident                                                                            |
| provided that | another charitable institution for dispensing to its patients, provided that  the following requirements are met:                               |
| until         | patient or be distributed to another charitable institution until it has been examined by a licensed practitioner                               |
| subject to    | (b) The drug origin statement is  subject to the record retention requirements of &#167;&#8201;203.60 and must                                  |
| when          | (c) Identifying statement not required  when  additional manufacturing processes are completed.                                                 |
| provided that | or by photographic imaging (i.e., photocopies or microfiche), provided that the security and authentication requirements described in paragraph |


## Entities

| Entities             | Context                                                                                                                                      |
|:---------------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Food                 | Food  and Drugs.                                                                                                                             |
| Scope                | Scope .                                                                                                                                      |
| Blood                | Blood and blood components intended for transfusion are excluded                                                                             |
| Purpose              | Purpose .                                                                                                                                    |
| Food                 | Food  and Drug Administration.                                                                                                               |
| United States        | manufactured in a State and exported from the United States may be reimported by anyone other than its                                       |
| Research             | regulated by the Center for Drug Evaluation and Research may be made to the Office of Compliance,                                            |
| Research             | regulated by the Center for Biologics Evaluation and Research may be made to the Food and Drug                                               |
| Rm                   | 71,  Rm .                                                                                                                                    |
| G112                 | G112 , Silver Spring, MD 20993-0002.                                                                                                         |
| Blood                | Blood establishments relying on the exclusion in this paragraph                                                                              |
| Sample               | Sample  distribution by mail or common carrier.                                                                                              |
| Sample               | Sample distribution by means other than mail or common                                                                                       |
| Risperidone          | (1 mg) returned to manufacturer&#8221; or simply &#8220; Risperidone (1 mg)/50/returned to manufacturer.&#8221; (3) Each drug manufacturer   |
| Drug                 | Drug  sample storage and handling requirements.                                                                                              |
| Drug                 | Drug  sample forms.                                                                                                                          |
| Fulfillment          | Fulfillment houses, shipping and mailing services, comarketing agreements, and                                                               |
| Investigation        | Investigation  and notification requirements.                                                                                                |
| Surveillance, Office | to the Division of Compliance Risk Management and Surveillance, Office of Compliance, Center for Drug Evaluation and Research,               |
| Research             | regulated by the Center for Drug Evaluation and Research shall be made to the Division of Compliance                                         |
| Research             | regulated by the Center for Biologics Evaluation and Research shall be made to the Food and Drug                                             |
| Rm                   | 71,  Rm .                                                                                                                                    |
| G112                 | G112 , Silver Spring, MD 20993-0002.                                                                                                         |
| Sample               | Sample  lot or control numbers; labeling of sample units.                                                                                    |
| Drug                 | Drug sample inventory discrepancies and reconciliation problems shall be                                                                     |
| Dosage               | proprietary and established name of the drug; (2) Dosage ;                                                                                   |
|                      |                       (3) Container size;                                                                                                    |
|                      |                       (4) Number of containers;                                                                                              |
| Request              | Request  and receipt forms, reports, and records.                                                                                            |
| Request              | Request and receipt forms, reports, records, and other documents                                                                             |
| Application          | Application  for a reward.                                                                                                                   |
| Research             | Office of Compliance, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                            |
| Research, Office     | and Drug Administration, Center for Biologics Evaluation and Research, Office of Compliance and Biologics Quality (ATTN: Director), Document |
| Rm                   | 71,  Rm .                                                                                                                                    |
| G112                 | G112 , Silver Spring, MD 20993-0002, as appropriate.                                                                                         |


